Evidence map›Paper›PMID 28155331›Full record

ArticleDrug delivery2017

Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.

Sandhya Pranatharthiharan, Mitesh D Patel, Vinod C Malshe, Vaishali Pujari, Ajit Gorakshakar, Manisha Madkaikar, Kanjaksha Ghosh, Padma V Devarajan

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 99 citations in OpenAlex.

  1. Article
  2. Poly(methyl vinyl ether-Polymers · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Sandhya Pranatharthiharana Department of Pharmaceutical Sciences and Technology , Institute of Chemical Technology (Deemed University, Elite Status) , Mumbai , Maharashtra , India and.
Mitesh D Patela Department of Pharmaceutical Sciences and Technology , Institute of Chemical Technology (Deemed University, Elite Status) , Mumbai , Maharashtra , India and.
Vinod C Malshea Department of Pharmaceutical Sciences and Technology , Institute of Chemical Technology (Deemed University, Elite Status) , Mumbai , Maharashtra , India and.
Vaishali Pujarib National Institute of Immunohaematology , Mumbai , Maharashtra , India.
Ajit Gorakshakarb National Institute of Immunohaematology , Mumbai , Maharashtra , India.
Manisha Madkaikarb National Institute of Immunohaematology , Mumbai , Maharashtra , India.
Kanjaksha Ghoshb National Institute of Immunohaematology , Mumbai , Maharashtra , India.
Padma V Devarajana Department of Pharmaceutical Sciences and Technology , Institute of Chemical Technology (Deemed University, Elite Status) , Mumbai , Maharashtra , India and.
National Institute of Immunohaematology · INUniversity of Mumbai · INInstitute of Chemical Technology · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report asialoglycoprotein receptor (ASGPR)-targeted doxorubicin hydrochloride (Dox) nanoparticles (NPs) for hepatocellular carcinoma (HCC). Polyethylene sebacate (PES)-Gantrez® AN 119 Dox NPs of average size 220 nm with PDI < 0.62 and ∼20% Dox loading were prepared by modified nanoprecipitation. ASGPR ligands, pullulan (Pul), arabinogalactan (AGn), and the combination (Pul-AGn), were anchored by adsorption. Ligand anchoring enabled high liver uptake with a remarkable hepatocyte:nonparenchymal cell ratio of 85:15. Furthermore, Pul-AGn NPs exhibited an additive effect implying incredibly high hepatocyte accumulation. Galactose-mediated competitive inhibition confirmed ASGPR-mediated uptake of ligand-anchored NPs in HepG2 cell lines. Subacute toxicity in rats confirmed the safety of the NP groups. However, histopathological evaluation suggested mild renal toxicity of AGn. Pul NPs revealed sustained reduction in tumor volume in PLC/PRF/5 liver tumor-bearing Nod/Scid mice up to 46 days. Extensive tumor necrosis, reduced collagen content, reduction in the HCC biomarker serum α-fetoprotein (p < 0.05), a mitotic index of 1.135 (day 46), and tumor treated/tumor control (T/C) values of <0.42 signified superior efficacy of Pul NPs. Furthermore, weight gain in the NP groups, and no histopathological alterations indicated that they were well tolerated by the mice. The high efficacy coupled with greater safety portrayed Pul Dox NPs as a promising nanocarrier for improved therapy of HCC.

Indexed as

Drug CarriersNanoparticlesalpha-FetoproteinsAnimalsAntibiotics, AntineoplasticAsialoglycoprotein ReceptorCarcinoma, HepatocellularCollagenDoxorubicinDrug CompoundingFemaleGalactansGlucansHep G2 CellsHumansLigandsAFP protein, humanalpha-FetoproteinsAntibiotics, AntineoplasticarabinogalactanAsialoglycoprotein ReceptorCollagenDoxorubicinDrug CarriersGalactansGlucansLigandsPolyesterspolyethylene sebacatepullulanarabinogalactanasialoglycoprotein receptordoxorubicin hydrochloridehepatocellular carcinomaPLC/PRF/5 liver tumorPullulan

Identifiers

PMID28155331
PMCPMC8244555
OpenAlexW2584917591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.